Skip to main content
S&P 5007,635.05+1.10%DOW51,790.42+0.64%NASDAQ26,402.79+1.63%BTC$76,673.00+1.14%ETH$2,467.44+2.97%GOLD$4,405.00+0.40%OIL$101.23-1.17%
Smart Investors Daily
LE

NASDAQ · LEXX

Lexaria Bioscience Corp.

Healthcare · Biotechnology

$3.10

Up+$0.43 (+13.73%)

Updated Sep 17, 2026, 3:01 PM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
22.39M
P/E ratio
-1.99
Dividend yield
0.00%
52-week range
$0.52 – $14.37
Volume
150.4K
Avg. volume
572.75K

Price performance

LEXX price history

1M range · 20 trading sessions · Daily adjusted prices

LEXX closed at $3.10 after 20 trading sessions, down 73.11% for the selected period.

Last close
$3.10
Period change
-73.11%
Period low
$3.10
Period high
$14.15
Daily close
View OHLC price history
LEXX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 16, 2026$3.28$3.47$2.8001$3.095150.4K
Sep 15, 2026$3.54$3.9316$2.98$3.21123.68K
Sep 14, 2026$3.98$4.15$3.14$3.55178.91K
Sep 11, 2026$4.15$4.72$3.645$3.97197.06K
Sep 10, 2026$7.00$7.50$4.04$4.05226.22K
Sep 9, 2026$9.44$9.52$6.405$6.6074.4K
Sep 8, 2026$11.09$11.09$8.81$9.37122.23K
Sep 4, 2026$12.26$14.37$12.26$14.1522.43K
Sep 3, 2026$13.33$13.93$12.25$12.3274.77K
Sep 2, 2026$12.63$13.61$12.40$13.20540.95K
Sep 1, 2026$11.13$12.89$11.13$12.47565.45K
Aug 31, 2026$10.30$12.20$10.30$11.28359.55K
Aug 28, 2026$11.42$12.475$10.35$10.3561.91K
Aug 27, 2026$10.97$11.78$10.24$11.68505.65K
Aug 26, 2026$11.70$11.90$11.00$11.045.23K
Aug 25, 2026$10.75$11.60$10.60$11.6012.33K
Aug 24, 2026$10.96$11.10$10.41$10.5414.94K
Aug 21, 2026$11.38$11.5299$10.80$10.9158.92K
Aug 20, 2026$11.96$12.8858$11.235$11.2767.11K
Aug 19, 2026$11.93$11.98$11.0569$11.51130.17K

Latest LEXX news

The latest Smart Investors Daily articles mentioning LEXX.

Stock researchCompany · Overview

LEXX research

Overview

Company profile and research snapshot.

Company profile

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
LEXX recent ratings
DateFirmRatingTarget
Dec 26, 2025HC Wainwright & Co.Buy—
Jul 29, 2025HC Wainwright & Co.Buy—
Jul 1, 2025HC Wainwright & Co.Buy—
Jan 24, 2025HC Wainwright & Co.Buy—
Dec 2, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

KELOWNA, BC / ACCESS Newswire / September 9, 2026 / (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today closed its previously announced exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise price of $45.

Yahoo · Sep 8, 2026

Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds

KELOWNA, BC / ACCESS Newswire / September 8, 2026 / (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase an aggregate of 453,969 shares of the Company's common stock originally issued by the Company on February 16, 2024, having an original exercise price of $32.78 per share, on October 16, 2024, having an original exercise

Yahoo · Sep 8, 2026

LEXX: Introducing DehydraTECH 3.0

By John Vandermosten, CFA NASDAQ: LEXX READ THE FULL LEXX RESEARCH NOTE Lexaria Bioscience Corp. (NASDAQ: LEXX) announced absorption data from its 2026 Animal Study #2 (GLP-1-A26-2). The canine study examined amycretin and retatrutide bioavailability using oral delivery compared to reference formats. 18 different study arms were evaluated, measuring tablets and capsules as well as DehydraTECH

Yahoo · Sep 4, 2026

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

KELOWNA, BC / ACCESS Newswire / September 4, 2026 / (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it will participate in the 28th Annual H. Wainwright Global Investment Conference, taking place September 14th through September 16th, 2026 in New York City.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By